SCMC Trial on KHE With KMP (V.2020)

• Status: Not yet recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Children's Medical Center
• Treatments: Sirolimus

Criteria

Inclusion Criteria:

• Kaposiform Hemangioendotheliomas with Kasabach-Merritt Phenomenon

• 0 - 12 years of age at the time of study entry

• Male or female

• Consent of parents (or the person having parental authority in families)

• Signed and dated written informed consent

Exclusion Criteria:

• with hematological diseases

• with other solid tumors

• with hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney

• dysfunction, and cardiopulmonary insufficiency

• with tuberculosis,cytomegalovirus and Epstein-Barr virus infection before the treatment